Search results for "Venous thromboembolism"
Risk for DVT, PE, bleeding after COVID-19, but low long-term VTE recurrence risk
One study found increased risk for deep venous thrombosis (DVT) for up to three months after COVID-19, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while another showed low rates of venous thromboembolism (VTE) recurrence in the year after infection.
https://acphospitalist.acponline.org/archives/2022/04/13/free/risk-for-dvt-pe-bleeding-seen-after-covid-19-long-term-risk-for-vte-recurrence-may-be-low.htm
13 Apr 2022
Comanage orthopedics like a pro
An expert offers her top 10 pearls.
https://acphospitalist.acponline.org/archives/2018/07/comanage-orthopedics-like-a-pro.htm
15 Jul 2018
VTE update covers new drugs, recommendations
Alternatives to warfarin will be available soon.
https://acphospitalist.acponline.org/archives/2010/07/vte.htm
15 Jul 2010
HCAP guidelines, CPR survival, and more
Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2018/04/recent-research.htm
15 Apr 2018
LMWH may offer best risk-benefit profile for thromboprophylaxis in medical inpatients
A meta-analysis found that an intermediate dose of low-molecular-weight heparin (LMWH) had the most favorable balance of risk and harms during hospitalization for acute illness, while unfractionated heparin and direct oral anticoagulants had the least.
https://acphospitalist.acponline.org/archives/2022/07/13/lmwh-may-offer-best-risk-benefit-profile-for-thromboprophylaxis-in-medical-inpatients.htm
13 Jul 2022
NIH guidelines on anticoagulation in COVID-19; research on statin use, omicron variant
The NIH updated its guidelines to address anticoagulation in COVID-19 inpatients, treatment with atorvastatin did not appear to improve outcomes in the ICU, and several studies looked at characteristics of omicron.
https://acphospitalist.acponline.org/archives/2022/01/12/free/nih-guidelines-on-anticoagulation-research-on-statins-and-COVID-19.htm
12 Jan 2022
New studies assess effects of anticoagulation during, after COVID-19
Use of intermediate, full-dose, or prophylactic anticoagulation in COVID-19 inpatients wasn't associated with any difference in in-hospital mortality in one study, while another found it was safe to discontinue anticoagulation after three months in patients with a COVID-19-associated clot.
https://acphospitalist.acponline.org/archives/2022/11/16/free/new-studies-assess-effects-of-anticoagulation-during-after-covid-19.htm
16 Nov 2022
qSOFA for mortality prediction, preoperative breathing exercises, and more
Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2018/07/recent-research.htm
15 Jul 2018
Higher-dose prophylactic anticoagulation required to prevent thrombosis in hypoxemic COVID-19
Mortality and time to improvement didn't differ with twice the standard dose of heparin versus a standard or therapeutic dose, but there was a lower rate of new thromboembolic events with no increase in major bleeding, a French trial found.
https://acphospitalist.acponline.org/archives/2023/03/29/free/higher-dose-prophylactic-anticoagulation-needed-to-prevent-thrombosis-in-hypoxemic-covid-19.htm
29 Mar 2023
Stroke imaging and AKI, beta-blockers after MI, and more.
Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2018/01/recent-research.htm
15 Jan 2018